BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Informa
Menu

Latest Pharma Insights



Basilea-Pfizer’s Cresemba Heads For Indian Debut
Basilea’s Cresemba appears on course to a debut in India and partner Pfizer expects the novel antifungal to bolster its...
The Pink Sheet - May 19, 2019
Celltrion To Invest $33.6bn As It Lays Out Long-Term Ambitions
Celltrion unveils massive long-term investment plan to secure leadership in the global biopharma market, set up international sales distribution networks...
The Pink Sheet - May 19, 2019
Cosmetics Weekly Trademark Review: May 14, 2019
Personal-care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3...
The Rose Sheet - May 19, 2019

£80m To Tackle Snakebite Is A Wellcome Boost
Two major initiatives have been announced which hope to revolutionize the treatment of snakebites, which claims the lives of up...
Scrip - May 17, 2019
Pharming Explores Further Uses For Ruconest
Pre-eclampsia and nephropathy associated with the use of contrast media in cardiac patients are two new potential uses for Pharming’s...
Scrip - May 17, 2019
Top Players In Clear After US Court Confirms Abiraterone Patent Is Invalid
The sole US patent listed against Janssen’s Zytiga abiraterone prostate-cancer treatment is invalid, the US Court of Appeals has confirmed...
Scrip - May 17, 2019
Teva Takes A Further Hit On Value Of Actavis
Teva has registered a further impairment of almost $500m, largely linked to the value of assets acquired when it took...
Scrip - May 17, 2019
BioGenetics Seeks To Boost Pharma Business Via Kyung Nam Acquisition
South Korean medical product manufacturer BioGenetics, which has recently diversified into the biopharma business and entered alliances for novel anticancer...
Scrip - May 17, 2019
Lupin Q4 Fails To Cheer But Signals Stabilization Of US Generic Market
Lupin’s management refer to multiple indicators suggesting the US generics segment is stabilizing. But traction for some key launches, delivering...
Scrip - May 17, 2019

Basilea-Pfizer’s Cresemba Heads For Indian Debut
Basilea’s Cresemba appears on course to a debut in India and partner Pfizer expects the novel antifungal to bolster its...
The Pink Sheet - May 19, 2019
Celltrion To Invest $33.6bn As It Lays Out Long-Term Ambitions
Celltrion unveils massive long-term investment plan to secure leadership in the global biopharma market, set up international sales distribution networks...
The Pink Sheet - May 19, 2019

Leading In Product Development Means Planning For All Eventualities
What is the cost of an adverse event, and the resulting safety action for a medical device that is already...
IN VIVO - May 16, 2019

BSI UK Rolls Out MDR Timeframe – But Warns Some Things Are 'Out Of BSI Control'
As of 3 June 2019, the notified body BSI UK will be accepting applications under the EU’s Medical Device Regulation...
Medtech Insight - May 17, 2019
Brazil Unifies Registration Coding For Imported And Home-Produced IVDs
In vitro diagnostic (IVD) product registrations in Brazil are now subject to the same procedures and codes, irrespective of whether...
Medtech Insight - May 17, 2019
QUOTED. 17 May 2019. Alexander Weber.
Alexander Weber, assistant professor of Sports Medicine in the USC Department of Orthopedic Surgery, told Medtech Insight that suture anchors have benefitted...
Medtech Insight - May 17, 2019

Cosmetics Weekly Trademark Review: May 14, 2019
Personal-care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3...
The Rose Sheet - May 19, 2019

Alvotech brings in $300mm through bond offering
Icelandic biosimilars firm Alvotech raised $300mm through a private bond offering from Morgan Stanley. The proceeds will help refinance existing debt and fund the company's continued growth and its biosimilars pipeline development. CSLA was the placement agent.
Strategic Transactions - May 18, 2019
Tmunity licenses pediatric brain cancer T-cell therapy from UCSF
Tmunity Therapeutics Inc. licensed exclusive rights to develop, manufacture, and commercialize T-cell therapies for rare pediatric cancers, with an initial focus on diffuse intrinsic pediatric glioma (DIPG).
Strategic Transactions - May 18, 2019
Curadev licenses STING agonist to Takeda
Curadev Pharma Pvt. Ltd. granted Takeda Pharmaceutical Co. Ltd. rights to develop and sell its STING (Stimulator of Interferon Genes) agonist molecule CDR5500 for solid tumors.
Strategic Transactions - May 18, 2019
Fuji licenses exclusive Japanese rights to Alvotech’s biosimilars pipeline; later takes minority stake
Fuji Pharmaceutical Co. Ltd. licensed exclusive Japanese development and commercialization rights to Alvotech’s biosimilars pipeline.
Strategic Transactions - May 18, 2019
Digital health start-up Tilak raises €2.5mm in early venture round
Digital health start-up Tilak Healthcare (prescribed therapeutic mobile games) raised €2.5mm ($2.7mm) in venture funding through an undisclosed early round, assumed to be its first, from the iBionext Growth Fund. Founded last year, the company is developing a mobile videogame platform used to monitor chronic diseases, with its first application targeting ophthalmology indications. Available through an app on a mobile device, the game--in which the patient completes a series of puzzles--is designed to screen for eye diseases by monitoring physician-defined visual parameters and generating remote notifications to the physician to enable prevention solutions and follow-up care. Tilak will use the proceeds to accelerate the deployment of its platform to doctors and patients.
Strategic Transactions - May 18, 2019
Neural Analytics raises $22mm Series C round
Neural Analytics Inc. (ultrasound technology to diagnose and monitor neurological disorders) closed a $22mm Series C round led by returning backer Alpha Edison. The company also issued warrants to purchase stock. The funding will enable Neural Analytics to expand commercialization of its Lucid robotic neurovascular ultrasound device. Designed to non-invasively search, measure, and display brain blood flow information in real-time, the Lucid device was FDA approved in 2016 and CE Marked in 2017 for use in traumatic brain injury assessment.
Strategic Transactions - May 18, 2019
Back to the top Back to the top